Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to -$363.4 million.

  • Haemonetics' Enterprise Value fell 1325.28% to -$363.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$363.4 million, marking a year-over-year decrease of 1325.28%. This contributed to the annual value of -$306.8 million for FY2025, which is 7156.77% down from last year.
  • As of Q4 2025, Haemonetics' Enterprise Value stood at -$363.4 million, which was down 1325.28% from -$296.4 million recorded in Q3 2025.
  • Haemonetics' 5-year Enterprise Value high stood at -$173.5 million for Q3 2021, and its period low was -$363.4 million during Q4 2025.
  • Over the past 5 years, Haemonetics' median Enterprise Value value was -$272.0 million (recorded in 2022), while the average stood at -$262.6 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 3714.54% in 2024, then crashed by 7156.77% in 2025.
  • Over the past 5 years, Haemonetics' Enterprise Value (Quarter) stood at -$192.4 million in 2021, then dropped by 16.41% to -$224.0 million in 2022, then grew by 13.4% to -$194.0 million in 2023, then tumbled by 65.4% to -$320.8 million in 2024, then dropped by 13.25% to -$363.4 million in 2025.
  • Its last three reported values are -$363.4 million in Q4 2025, -$296.4 million for Q3 2025, and -$292.9 million during Q2 2025.